RA CAPITAL MANAGEMENT, L.P. Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001346824

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltHigh Turnover how tags are computed

Q2 2025 · 63 positions · Total reported value $5.94B · Top-10 concentration 66.2% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 38.4% · 15 new · 12 cut · 11 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -13.6% · vs SPY -15.8% · Prev Value $11.51B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -1.6% · vs SPY -3.7% · Latest Value $9.72B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q2 2025 13F filing, RA CAPITAL MANAGEMENT, L.P. disclosed 63 equity positions with a combined reported value of $5.94B. The filing implies a focused portfolio: its ten largest positions account for 66.2% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2025 were ASND ($1.77B), PCVX ($389.01M), RYTM ($351.42M). By sector, the heaviest allocations are Health Care 85.6%, Technology 0.3%. Versus the prior quarter, allocation shifted toward Other (+0.8pp) and away from Health Care (-0.5pp).

Versus the prior quarter, RA CAPITAL MANAGEMENT, L.P. opened 15 new positions, trimmed 12 and fully exited 11, a turnover rate of 38.4% of positions. The portfolio's overlap with the prior quarter was 63% of names.

The largest new positions opened in Q2 2025 were HNGE ($15.53M), JBIO ($10.61M), TNGX ($10.24M).

Of the 11 positions fully exited versus the prior quarter, the largest were APGE ($58.64M), ZLAB ($46.80M), DAWN ($45.64M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2025)

  • HNGE HINGE HEALTH INC · $15.53M
  • JBIO JADE BIOSCIENCES INC · $10.61M
  • TNGX TANGO THERAPEUTICS INC · $10.24M
  • OMDA OMADA HEALTH INC · $7.32M
  • WGS GENEDX HOLDINGS CORP · $5.36M
  • IFRX INFLARX NV · $1.56M

Fully Exited (vs previous quarter)

  • APGE APOGEE THERAPEUTICS INC · prev qtr: $58.64M
  • ZLAB ZAI LAB LTD · prev qtr: $46.80M · history
  • DAWN DAY ONE BIOPHARMACEUTICALS I · prev qtr: $45.64M
  • URGN UROGEN PHARMA LTD · prev qtr: $35.46M
  • ATXS ASTRIA THERAPEUTICS INC · prev qtr: $27.26M
  • KURA KURA ONCOLOGY INC · prev qtr: $26.43M
  • AVTE AEROVATE THERAPEUTICS INC · prev qtr: $23.07M
  • IDYA IDEAYA BIOSCIENCES INC · prev qtr: $22.07M

Insider Transactions (Form 4)

Latest RA CAPITAL MANAGEMENT, L.P. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-11-02 Buy Bambusa Therapeutics, Inc. 164,891 $16.00 SEC filing
2026-11-02 Buy Bambusa Therapeutics, Inc. 2,335,109 $16.00 SEC filing
2026-11-02 Conversion Bambusa Therapeutics, Inc. 1,331,080 — SEC filing
2026-11-02 Conversion Bambusa Therapeutics, Inc. 3,144,858 — SEC filing
2026-10-30 Buy Bambusa Therapeutics, Inc. 263,911 $14.92 SEC filing
2026-10-30 Buy Bambusa Therapeutics, Inc. 189,909 $14.23 SEC filing
2026-10-29 Sell LENZ Therapeutics, Inc. 107,170 $3.36 SEC filing
2026-10-29 Sell LENZ Therapeutics, Inc. 451,998 $3.36 SEC filing

All insider transactions →

Fund Profile

RA Capital Management is a Boston-based investment firm founded by Peter Kiernan, specializing in healthcare-focused investments with a long-term, value-oriented approach.

Investment Approach

Focuses on healthcare sector investments

Long-term, value-oriented strategy

Deep fundamental research and analysis

Asset Classes & Strategy

Primarily invests in public equities

Also manages private investments in healthcare companies

Concentrated portfolio approach with significant positions in healthcare companies

Key Personnel

Peter Kiernan: Founder and portfolio manager

Team of experienced investment professionals with healthcare expertise

Notable Facts

Founded in 2002

Manages approximately $16.4 billion in assets

Files SEC Form 13F for US equity positions

This profile is based on publicly available information and should not be considered as official disclosure from the firm.

Sector Allocation

Health Care 85.6%
Technology 0.3%
Materials 0.0%
Other 14.0%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 10.28M $1.77B 29.90%
29.90%
Hold
2 11.97M $389.01M 6.55%
6.55%
Reduce
3 5.56M $351.42M 5.92%
5.92%
Reduce
4 11.19M $258.48M 4.36%
4.36%
Hold
5 7.27M $206.36M 3.48%
3.48%
Add
6 3.04M $199.96M 3.37%
3.37%
Hold
7 19.89M $195.32M 3.29%
3.29%
Hold
8 10.86M $189.52M 3.19%
3.19%
Hold
9 10.14M $183.62M 3.09%
3.09%
Hold
10 10.45M $181.23M 3.05%
3.05%
Hold
11 3.37M $163.93M 2.76%
2.76%
Add
12 9.90M $129.82M 2.19%
2.19%
Add
13 4.18M $122.48M 2.06%
Form 4 · 3 →
2.06%
Hold
14 18.20M $118.31M 1.99%
Form 4 · 1 →
1.99%
Hold
15 12.20M $116.74M 1.97%
1.97%
Add
16 7.68M $93.58M 1.58%
1.58%
Add
17 9.71M $92.48M 1.56%
1.56%
Hold
18 60.38M $85.13M 1.43%
1.43%
Hold
19 1.58M $83.52M 1.41%
1.41%
Hold
20 6.15M $83.17M 1.40%
1.40%
Hold
21 7.00M $73.95M 1.25%
1.25%
Hold
22 10.23M $70.38M 1.19%
1.19%
Hold
23 6.96M $64.62M 1.09%
1.09%
Hold
24 39.65M $64.23M 1.08%
Form 4 · 1 →
1.08%
Hold
25 23.56M $54.41M 0.92%
0.92%
Add
26 2.87M $53.41M 0.90%
0.90%
Hold
27 3.70M $48.14M 0.81%
0.81%
Reduce
28 2.54M $40.60M 0.68%
0.68%
Hold
29 1.14M $40.25M 0.68%
0.68%
Hold
30 31.42M $38.96M 0.66%
Form 4 · 4 →
0.66%
Hold
31 1.52M $31.47M 0.53%
0.53%
Hold
32 5.81M $28.30M 0.48%
0.48%
Add
33 675.52K $19.22M 0.32%
0.32%
Hold
34 511.21K $18.29M 0.31%
0.31%
Hold
35 10.81M $17.94M 0.30%
0.30%
Hold
36 6.05M $17.47M 0.29%
0.29%
Hold
37 14.93M $17.32M 0.29%
0.29%
Hold
38 848.99K $17.03M 0.29%
0.29%
Hold
39 1.15M $17.02M 0.29%
0.29%
Hold
40 4.56M $16.93M 0.28%
0.28%
Hold
41 300.00K $15.53M 0.26%
0.26%
New
42 9.85M $14.88M 0.25%
0.25%
Hold
43 10.69M $11.87M 0.20%
0.20%
Hold
44 1.06M $10.61M 0.18%
0.18%
New
45 2.00M $10.24M 0.17%
0.17%
New
46 8.34M $9.93M 0.17%
0.17%
Hold
47 3.57M $9.66M 0.16%
0.16%
Hold
48 1.14M $9.25M 0.16%
0.16%
Hold
49 750.00K $7.96M 0.13%
0.13%
Hold
50 400.00K $7.32M 0.12%
0.12%
New

FAQ

What did RA CAPITAL MANAGEMENT, L.P. buy in 2025-Q2?

In its 2025-Q2 13F filing, RA CAPITAL MANAGEMENT, L.P. reported 63 equity positions worth $5.94B in aggregate; its largest disclosed positions were ASND ($1.77B), PCVX ($389.01M), RYTM ($351.42M).

How large is RA CAPITAL MANAGEMENT, L.P.'s portfolio?

RA CAPITAL MANAGEMENT, L.P. reported $5.94B of long equity holdings across 63 positions as of 2025-Q2. Top-10 holdings account for 66.2% of reported value.

What is RA CAPITAL MANAGEMENT, L.P.'s investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/ra-capital-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →